← Eichor
Study identifier: NCT05985863 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure

Condition: Acute-On-Chronic Liver Failure  ·  Sponsor: Beijing 302 Hospital

PhasePhase 1/Phase 2
Planned participants150
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

This study is a randomized double-blind placebo-controlled multicenter clinical trial to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell (UC-MSC) transplantation for the treatment of acute-on-chronic liver failure (ACLF). UC-MSC therapy may improve the clinical outcomes of patients with ACLF. The trial would provide scientific evidence for UC-MSC transplantation as a potential treatment for ACLF.

This description comes directly from the study's public registry record.

Talk to the study team

Tao Yang, MD  ·  86-010-66933333  ·  y_t_0321@163.com

Yanhu Wang, MM  ·  86-010-66933328  ·  2440477984@qq.com

Always discuss trial participation with your own doctor first.

Locations (1)

the Fifth Medical Center, Chinese PLA General HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05985863